Cross-Sector entity
ClaimsFiler is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The 168-day window averages about 0.1 stories each week. The busiest single day carried 2. The clearest coverage concentration is gene-therapy: 1 of 3 stories, with the rest divided among 2 other categories.
3 verified stories tracked
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ClaimsFiler is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The 168-day window averages about 0.1 stories each week. The busiest single day carried 2. The clearest coverage concentration is gene-therapy: 1 of 3 stories, with the rest divided among 2 other categories. We currently track 3 Cross-Sector stories that mention uniQure N.V., published between February 19, 2026 and August 5, 2026. The tracked stories average 2.3 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering uniQure N.V.. Shared-story counts are live from our verified record — not editorial picks.
Anticipated Amended Complaint
Expected filing of detailed allegations following the appointment of lead plaintiffs.
SEC filings and market close
Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
Insider sales executed
Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
Q1 2026 earnings
uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
Lead Plaintiff Deadline
Final date for eligible investors to file applications to lead the class action lawsuits.
Judicial Review
Courts expected to begin selecting lead plaintiffs and lead counsel for the consolidated cases.
RBC upgrade
RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.
Shareholder Alerts Issued
ClaimsFiler releases formal reminders for KD and QURE investors regarding legal deadlines.
Legal Alert Issued
ClaimsFiler reminds shareholders of upcoming deadlines for lead plaintiff applications.
Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Source: dailypolitical.com · themarketsdaily.com
Investors in uniQure N.V. and Kyndryl Holdings have until April 13, 2026, to file as lead plaintiffs in securities class action lawsuits following significant stock losses. The litigation highlights increasing regulatory and disclosure pressures on biotech firms specializing in complex gene therapies.
ClaimsFiler has issued a critical reminder for investors in Kyndryl Holdings and uniQure N.V. regarding upcoming lead plaintiff deadlines in ongoing securities class action litigation. Shareholders with losses exceeding $100,000 have until April 13, 2026, to seek lead plaintiff status in cases alleging potential violations of federal securities laws.
Source: Postregister · Hastingstribune
